One in two women at high risk of bone fractures don't receive preventative treatment, according to new research presented at the British Pharmaceutical Conference (BPC) in Manchester.
Pharmacists in Northumberland,(i) where the hip fracture hospital admission rate is one of the highest in the UK, conducted the study. The study groups also included North Tyneside, which has a high mortality rate after falls.(1)
According to the National Institute for Health and Clinical Excellence (NICE), women who have had a previous "fragility" bone fracture or are diagnosed with osteoporosis1; and women over 75 with osteoporosis, or who have had a fragility fracture; should receive treatment with calcium/vitamin D3 and bisphosphonate.(1)
The new research aimed to find out if the NICE criteria and bone protection treatments were being met in a general practice population. The results showed that of the patients found to be at risk of future fractures, only half were receiving the recommended bone protection treatment (calcium/vitamin D3 with a bisphosphonate).
Those aged below 74 and at risk should have treatment based on the results of a bone scan, but the study showed this occurred in only a quarter of all cases.
Pharmacy research into medicine-taking for osteoporosis in Glasgow, Scotland, looked at whether patients were compliant with taking medications they had been prescribed for osteoporosis. They found that of the 353 at-risk patients, 70% were taking a bisphosphonate and calcium supplement as osteoporosis prevention therapy, but almost a quarter did not always take their medication.
The reasons patients listed for not taking their medicine included that they: forgot (46%); disliked the taste (22%); were fed up taking it (7%) and were unsure of the indication (2%). Others did not understand sufficient detail about the appropriate way to take the medication.